How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4159-4161

  Moore, Richard G ^a   Bast, Robert C ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TUMOR MARKER; MONOCLONAL ANTIBODY;

AGE DISTRIBUTION; ANALYTICAL PARAMETERS; ANTIBODY DETECTION; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; EARLY CANCER; ECONOMIC ASPECT; EDITORIAL; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS CANCER; PELVIS TUMOR; POPULATION RISK; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRANSVAGINAL ECHOGRAPHY; TUMOR DIAGNOSIS; ADULT; ALGORITHM; CHEMISTRY; ECHOGRAPHY; FEMALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NOTE; ONCOLOGY; OVARY TUMOR; PREMENOPAUSE; RISK; ROC CURVE;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PREMENOPAUSE; RISK; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 34948853253     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9594     Document Type: Editorial

References (24)

1. Bast RC Jr, Feeney M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337, 1981
2. Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887, 1983
3. Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306:1030-1034, 1993
4. Hawkins RE, Roberts K, Wiltshaw E, et al: The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 96:1395-1399, 1989
5. Rustin GJ, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996
6. Gadducci A, Cosio S, Zola P, et al: Surveillance procedures for patients treated for epithelial ovarian cancer: A review of the literature. Int J Gynecol Cancer 17:21-31, 2007
7. Sugiyama T, Nishida T, Komai K, et al: Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet 54:251-256, 1996
8. Skates SJ, Menon U, MacDonald N, et al: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21:206-210, 2003 (suppl)
9. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3:355-366, 2004
10. Goodman MT, Howe HL: Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer 97:2615-2630, 2003 (suppl)
11. Chan JK, Cheung MK, Husain A, et al: Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108:521-528, 2006
12. Earle CC, Schrag D, Neville BA, et al: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172-180, 2006
13. McGowan L, Lesher LP, Norris HJ, et al: Misstaging of ovarian cancer. Obstet Gynecol 65:568-572, 1985
14. Olaitan A, Weeks J, Mocroft A, et al: The surgical management of women with ovarian cancer in the south west of England. Br J Cancer 85:1824-1830, 2001
15. Paulsen T, Kjaerheim K, Kaern J, et al: Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16:11-17, 2006 (suppl 1)
16. Engelen MJ, Kos HE, Willemse PH, et al: Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106:589-598, 2006
17. Giede KC, Kieser K, Dodge J, et al: Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 99:447-461, 2005
18. Bast RC Jr, Urban N, Shridhar V, et al: Early detection of ovarian cancer: Promise and reality. Cancer Treat Res 107:61-97, 2002
19. Moore RG, Brown AK, Miller CM, et al: A novel multiple biomarker assay for the detection of ovarian carcinoma. J Clin Oncol 24:261s, 2006 (abstr 5023)
20. Jacobs I, Oram D, Fairbanks J, et al: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97:922-929, 1990
21. DePriest PD, Shenson D, Fried A, et al: A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 51:7-11, 1993
22. Timmerman D, Testa AC, Bourne T, et al: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: A multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 23:8794-8801, 2005
23. Timmerman D, Van Claster B, Jurkovic D, et al: Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol 25:4194-4200, 2007
24. Carney ME, Lancaster JM, Ford C, et al: A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84:36-42, 2002